 | |
         | |
  Filling the gaps in HAT drug development Currently, few drugs exist for the treatment of either Stage 1 or Stage 2 human African trypanosomiasis (HAT), and severe toxic side effects are a common problem. The difficulty of diagnosis, stage determination, and increasing numbers of treatment failures pose additional clinical challenges. The overall strategy of DNDi is to build a dynamic portfolio to fill the numerous gaps in the drug pipeline that have led to few drugs developed for HAT patients...  | ||
 | ||
 Nifurtimox-eflornithine: a simpler, safer, and more effective combination for stage 2 HAT patients Each of the few drugs available for people suffering from stage 2 HAT has problems of toxicity, efficacy, and complicated use, and/or the risk of developing resistance...  The French Development Agency commits €1.5 million to DNDi The grant from the Agence Française de Développement (AFD) is to support the development of DNDi’s two new drugs for malaria artesunate/amodiaquine and artesunate/mefloquine, which combine two proven antimalarials in fixed doses in a single tablet...  |  FINDing an alternative to improve diagnostics for HAT and other poverty-related Control of human African trypanosomiasis (HAT) depends primarily on a combination of active and passive case detection and curative treatment...   | |
Published by Drugs for Neglected Diseases Initiative - 1 Place St Gervais 1201 Geneva Switzerland - Photo credits: DNDi
Editor: Ann-Marie Sevcsik - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org
Editor: Ann-Marie Sevcsik - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org